相关实验视频
Updated: Jun 4, 2025

07:09
The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
Published on: July 16, 2014
48.1K
米罗加巴林作为神经病痛治疗的治疗选择 新兴的牙后内科治疗:一项观察性研究
Kohei Shimizu1, Takuya Yasukawa1, Takuro Izumida2
1Department of Endodontics, Nihon University School of Dentistry, Tokyo, Japan; Division of Advanced Dental Treatment, Dental Research Center, Nihon University School of Dentistry, Tokyo, Japan.
Journal of endodontics
|December 30, 2024
概括
在内治疗后,米罗加巴林有效治疗创伤后三角神经病痛 (PTTN-闭塞性疼痛). 这种药物允许在第11周减少剂量和停止治疗,而不会导致疼痛复发.
科学领域:
- 神经学 神经学
- 牙科 牙科是指牙科的专业.
- 药理学 药理学是指药理学的学科.
背景情况:
- 在内治疗后的创伤后三角神经病变疼痛 (PTTN-闭塞性疼痛) 提出了临床挑战.
- 米罗加巴林最近在这种特定的疼痛条件上显示出临床疗效.
研究的目的:
- 为了确定最佳的米罗加巴林的服用时间和剂量逐渐减少的策略.
- 建立基于临床病例管理的PTTN闭合性疼痛管理指南.
主要方法:
- 患有PTTN闭合性疼痛的患者被分为临时恢复 (n=13) 和米罗加巴林药物 (n=15) 组.
- 服用米罗加巴林 (10毫克/天),并使用视觉模拟量表 (VAS) 日记监测疼痛强度.
- 根据患者的适应性和疼痛水平,评估了剂量减少和停药方案.
主要成果:
- 临时恢复组显示,从第6周开始,VAS得分显著下降.
- 从第一周开始,米罗加巴林组表现出显著的VAS得分减少.
- 米罗加巴林在第7周左右逐渐减少,并在第11周停止使用,没有观察到疼痛复发.
结论:
- 米罗加巴林是一种有效的治疗PTTN闭合性疼痛.
- 建议治疗时间大约为11周,剂量逐渐逐渐降低.
- 这项研究为使用米罗加巴林治疗PTTN闭合性疼痛提供了基础.
相关概念视频
Analgesia and Pain Management
496
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
496
Opioid Analgesics: Synthetic and Semisynthetic Opioids
219
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
219
Antiepileptic Drugs: Potassium Channel Activators
143
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
143

